5-Methyltetrahydrohomofolate.
5-methyltetrahydrohomofolate was developed in the 1970's as an antifolate with the potential to overcome methotrexate resistance. This review summarizes the preclinical and clinical data which have accumulated to date. It is concluded that more recent, better characterized antifolates offer greater potential in achieving the goals for which this drug was introduced.
O'Dwyer
P J
PJ
Investigational Drug Branch, National Cancer Institute, Philadelphia.
Wagner
B H
BH
Hoth
D F
DF
Leyland-Jones
B
B
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004341:Drug Evaluation; D005492:Folic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005493:Folic Acid Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans
D000964:Antimetabolites, Antineoplastic; D005493:Folic Acid Antagonists; C020410:5-methyltetrahydrohomofolic acid; D005492:Folic Acid